Clinical Trials Logo

Clinical Trial Summary

This purpose of this clinical research is to determine the efficacy and safety of an experimental drug called rilonacept in subjects with an acute gout attack. Subjects will participate in in this study for 30 days. Rilonacept alone is being compared with indomethacin alone and the combination of rilonacept plus indomethacin in treating acute gout flares.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00855920
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date March 2009
Completion date February 2010

See also
  Status Clinical Trial Phase
Recruiting NCT05658575 - Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Phase 2/Phase 3